<DOC>
	<DOCNO>NCT02946333</DOCNO>
	<brief_summary>Those patient newly diagnose Multiple Myeloma ( MM ) candidate Autologous Stem Cell Transplant ( ASCT ) meet screen criterion describe protocol participate . The participate patient must sign informed consent , investigator collect study variables electronic case report form ( eCRF ) provide . The investigator must recruit least 450 patient 24-month period .</brief_summary>
	<brief_title>A Study Assess Disease Burden , Terms Health-related Quality Life Direct Healthcare Costs , Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates Autologous Stem Cell Transplant ( ASCT ) Spain</brief_title>
	<detailed_description>Following baseline enrolment visit , follow data correspond patient 's visit schedule accord routine clinical practice collect accordance follow model : 1 . Recruitment period : data collection baseline visit , every 4 month +/- 15 day first year ( month 4 , 8 12 ) every 6 month +/- 1 month second year ( month 18 24 ) . 2 . Follow-up period : ( study end 4 year follow enrolment first patient ) - From month 24 4 year enrolment first patient , follow-ups perform semi-annual data collection coincide patient 's routine clinical practice visit . - In case progression , suspension unexpected termination treatment ( example due toxicity ) , death , data collection coincide visit case present occurs perform . - If new line treatment start , follow-up model start frequency follow-up describe point 1 ( month 4 , 8 , 12 , 18 24 semi-annually accord routine clinical practice 4 year enrolment first patient study ) . 3 . Observation period : Following 4-year period , additional 5-year follow-up perform evaluate onset second primary malignant neoplasm . This follow-up 5-year observational period perform semi-annually ( ± 1 month ) accord routine clinical practice site .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patient ≥ 18 year age . Patient newly diagnose multiple myeloma ( MM ) accord IMWG criterion candidate ASCT start treatment study disease . Patient capable understand fill study questionnaire . Patient grant informed consent write . Patient participate active phase treatment clinical trial study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>autologous stem cell transplant ( ASCT )</keyword>
	<keyword>QoLMMBuS</keyword>
	<keyword>healthcare cost</keyword>
</DOC>